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Abstract
Background: Dental caries incidence in adults is similar to that in children and adolescents, but few caries
preventive agents have been evaluated for effectiveness in adults populations. In addition, dentists direct fewer
preventive services to their adult patients. Xylitol, an over-the-counter sweetener, has shown some potential as a
caries preventive agent, but the evidence for its effectiveness is not yet conclusive and is based largely on studies
in child populations.
Methods/Design: X-ACT is a three-year, multi-center, placebo controlled, double-blind, randomized clinical trial
that tests the effects of daily use of xylitol lozenges versus placebo lozenges on the prevention of adult caries. The
trial has randomized 691 participants (ages 21-80) to the two arms. The primary outcome is the increment of
cavitated lesions.
Discussion: This trial should help resolve the overall issue of the effectiveness of xylitol in preventing caries by
contributing evidence with a low risk of bias. Just as importantly, the trial will provide much-needed information
about the effectiveness of a promising caries prevention agent in adults. An effective xylitol-based caries
prevention intervention would represent an easily disseminated method to extend caries prevention to individuals
not receiving caries preventive treatment in the dental office.
Trial Registration: ClinicalTrials.Gov NCT00393055.
Background
Dental caries is a significant problem for adults. Despite a
widely held perception that caries is a disease of child-
hood, it has become clear that the incidence of new lesions
in adults is approximately the same as the incidence in
adolescents [1]. Dentistry has been slow to recognize and
address this problem. Specifically, caries preventive proce-
dures have been infrequently provided to adults in the
past [2], although a recent report does suggest that den-
tists are now more likely to provide such procedures if
they identify an adult patient as “caries active” [3].
While it is likely that there are several reasons for the
dental profession’s inattention to the prevention of car-
ies in adults, lack of evidence about the effectiveness of
preventive treatments in adults may be an important
factor. Presumably, this lack of evidence contributes to
practitioners’ reluctance to provide preventive treatment
to adults, and may limit purchasers’ enthusiasm for
coverage for such treatment. The National Institutes of
Health Consensus Development Conference on Diagno-
sis and Management of Dental Caries Throughout Life
noted that virtually all of the dental profession’s knowl-
edge concerning the effectiveness of caries preventive
interventions had come from trials in children and ado-
lescents [4]. The Conference recommended additional
caries trials in adults.
In response to that recommendation we designed a
randomized clinical trial, the Xylitol for Adult Caries
Trial (X-ACT), to test the hypothesis that use of xylitol
lozenges will reduce dental caries incidence in caries-
active adults. At the time that the trial was designed,
three reviews of the effectiveness of xylitol had appeared
[5-7]. Although each review found evidence for a xylitol
preventive effect, two reviews indicated that the available
evidence was not strong enough to permit a firm con-
clusion of therapeutic effectiveness. All of the reviews
indicated that the existing evidence needed to be sup-
plemented by well-designed trials. Because xylitol is
already approved as an over-the-counter sweetener, the
intervention could be delivered outside the context of a
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implementation feasible. In addition, delivery through
candy, gum, or lozenges (mints) would be likely to pro-
mote adherence to the preventive regimen. This paper
describes the X-ACT protocol.
Methods/Design
X-ACT is a three-year, multi-center, placebo-controlled,
double-blind, randomized clinical trial sponsored by the
National Institute of Dental and Craniofacial Research
(NIDCR) that tests the effects on caries progression of
daily use of xylitol lozenges versus placebo lozenges.
The trial takes place in three clinical centers, which are
located in the dental schools of the University of North
Carolina-Chapel Hill, the University of Texas Health
Sciences Center-San Antonio, and the University of Ala-
bama-Birmingham. The Data Coordinating Center
(DCC) is at the Kaiser Permanente Center for Health
Research-Portland, Oregon. A Data and Safety Monitor-
ing Board appointed by NIDCR provides oversight. The
study was approved by the Institutional Review Boards
at each site and all participants provided written
informed consent. An overview of participant flow
through the study is shown in Figure 1. Key features are
a run-in period before randomization and regular con-
tact of clinical staff with participants throughout the
intervention period.
Study Population
Principal inclusion criteria were age 21-80 and the pre-
sence of at least one coronal or root surface cavitated
caries lesion (either present at screening or documented
in the dental record within the past 12 months). The
caries criterion was designed to include participants
who were at risk of forming new lesions. Similarly, to
ensure an adequate quantity of surfaces at risk, partici-
pants were required to have a minimum of 12 teeth
with exposed coronal or root surfaces. In addition, parti-
cipants had to be able to read and comprehend study
materials in English, and be able to give informed con-
sent. Exclusion criteria consisted of having more than
10 teeth with caries lesions, having Type IV periodonti-
tis, receiving long-term antibiotic therapy, needing anti-
biotic prophylaxis prior to dental treatment, having
history of head and neck radiation therapy, a history of
adverse reaction to either placebo or intervention agent,
a serious illness that would interfere with participation,
plans to leave the area within the next three years, no
telephone, a member of the household already enrolled
in the trial, or investigator option.
Study Treatments
The intervention consisted of consumption of five
lozenges daily. We chose lozenges as the delivery
method on the basis of a report that lozenges were
strongly preferred to gum i nas a m p l eo fv e t e r a n s[ 8 ]
and our own perception that gum would be objection-
able to some proportion of potential participants.
Each active lozenge contained 1.0 g of xylitol as a
sweetening agent. The placebo lozenge was identical in
size and color to the active lozenge but was sweetened
with sucralose, which lacks any plausible biologic
recruitment/enrollment
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Figure 1 Trial Design and Participant Contacts.
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lozenges were peppermint flavored. The lozenge used
for the run-in period was also sweetened with sucralose,
but was spearmint flavored to avoid inadvertent
unblinding of participants.
The available literature suggests, but does not demon-
strate conclusively, a possible threshold of caries preven-
tion effectiveness around 3 exposures each day with a
total daily intake of 3-4 g [9]. Because we were unable
to identify a manufacturer capable of compounding
both active lozenges containing more than 1 g of xylitol
and indistinguishable placebo lozenges, our choice of a
5 lozenge/day regimen represents a compromise
between increased assurance of achieving a therapeutic
dose and practicality.
Since xylitol has the capacity to act as a laxative in
some individuals, participants were asked to gradually
increase the number of lozenges they took each day
from 1 to 5 during the first 10 days. This “ramping up”
was done both during the run-in period and at the
initiation of the intervention post randomization.
Lozenges were supplied to participants in containers
of 75, with the participant’s ID number permanently
marked on the container. Seven containers constituted a
3-month supply with some extra lozenges. Participants
also received a pocket container capable of holding a
day’s supply of five lozenges. The active and placebo
lozenges were prepared in separate manufacturing runs,
and samples of each run were assayed to confirm the
xylitol content. The lozenge used during the run-in per-
iod was also prepared in a separate run, but was not
assayed.
Study Schedule
Figure 1 summarizes the trial flow from a participant’s
perspective. The study requires a participant to visit the
clinic a minimum of 5 times. Screening was followed as
soon as possible by an enrollment visit. The enrollment
visit is followed by a placebo run-in period. Adherent,
eligible enrollees were randomized at the baseline visit.
Participants are then scheduled to return at 12 months,
24 months and 36 months for caries examinations, with
quarterly telephone contacts between examination visits.
Before the 24-month visits began, the final examination
schedule was shifted to 33 months, to adjust for slower
than expected completion of enrollment.
Recruitment, Run-in and Enrollment
Recruitment of potential study participants began in
April 2007, and ended in September 2008. Although the
primary pool of potential study participants was dental
school patients, low yields prompted two sites to expand
recruitment efforts to the general public via solicitations
at public dental clinics and mass media advertising. All
enrollment visits were preceded by a brief conversation
by telephone or in person during which eligibility and
interest were assessed. Where possible, additional initial
screening was accomplished by review of electronic or
paper clinical records. All potential study participants
attended an enrollment visit where eligibility was verified,
the study was described, and requirements of participa-
tion were reviewed. Those individuals who indicated a
willingness to enroll participated in a four-week run-in
period [10] to help identify potential participants who
were unable or unwilling to adhere to the study regimen.
A call midway through the run-in period was used for
data collection (adherence, side effects) and encourage-
ment. Ultimately, 27% of those who entered the run-in
period did not continue to randomization [11]. Enrollees
received no financial incentives for participation in the
run-in period. Financial incentives, in the form of cash
payments and travel expense reimbursements, were avail-
able for enrollees who continued to the full trial.
Randomization and Treatment Contacts
Those enrollees who completed the run-in period with
adequate self-reported adherence (consumption of more
than half of lozenges scheduled during the run-in per-
iod) and who indicated a willingness to participate in
the full trial attended a baseline visit wherein eligibility
criteria were confirmed, and a caries examination was
performed. Eligible enrollees were randomized to either
the active or placebo arm, additional information was
collected, and the initial supply of lozenges was dis-
pensed. Randomization was carried out using a web-
based randomization application process. Allocation
assignments were stratified by site and age group (≥ 50,
< 50 yrs.) in permuted blocks of varying sizes within
each stratum. Staff and participants were blinded to
treatment assignment. A total of 691 participants were
randomized, 92% of the goal of 750.
In the periods between the visits for caries examina-
tions, participants are contacted by telephone on a quar-
terly basis to assess adherence, side effects, receipt of
preventive dental care; to screen for possible serious
adverse events; and to arrange for re-supply of lozenges.
Participants are asked how many unopened bottles they
have on hand, and sufficient bottles for the next three
months are dispensed from the participant’s master sup-
ply at the clinical site and are delivered by courier.
Caries Examination
Caries are diagnosed visually by calibrated examiners
using a CPITN-E probe, a non-magnifying plane mirror;
and standard dental operating light and chair. Loupes
are used at the discretion of the examiner, but consis-
tently within each examiner. Tooth surfaces are dried
for five seconds with an air/water syringe.
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and Fyffe [12] to classify the status of each tooth sur-
face; however, the descriptors in X-ACT are a modifica-
tion of the 2-digit numeric codes in the International
Caries Detection and Assessment System II (ICDAS II)
[13,14]. ICDAS II has established objective clinical signs
that are associated with severity levels of dental caries,
verified histologically. The X-ACT taxonomy does not
make a number of distinctions that are in the ICDAS II
taxonomy. Instead, we have collapsed codes as follows:
￿ First digit codes: 0 is signified by S(sound); 1, 2 are
collapsed into P (pits and fissures sealed surface); 3,
4, 7, 8 are collapsed into F(filled); and 5, 6 are col-
lapsed into C(crowned);
￿ Second digit codes: 0 is signified by S; 1, 2 are col-
lapsed into a single D1 code (uncavitated lesion); 3,
4 are collapsed into a single D2 code (cavitated
lesion penetrating the enamel); and 5, 6 were col-
lapsed into a single D3 code (cavitated lesion pene-
trating into the dentin).
￿ Codes 97, 98 were collapsed into M (missing); 96,
99 into Y (unscorable or invisible surface)
For purposes of scoring our outcome measures, calls
distinguished by P as the first character are collapsed
into the most similar caries status category (see Table 1,
e.g., PD2 with D2), since transition to or from a surface
with pits & fissure sealant (P) does not indicate a
change in caries status. Calls that signify the need for
surgical intervention are treated identically, so the D2
and D3 calls are collapsed into one category. For our
primary outcome, calls that do not require surgical
intervention (S, D1) are collapsed into one category.
Finally, in contrast to ICDAS II, examiners make only
one diagnostic judgment per tooth surface. Each central,
lateral, and canine tooth is deemed to have five coronal
(including the incisal) surfaces and four root surfaces.
A primary examiner at each clinical center is sched-
uled to complete virtually all examinations. A back-up
examiner can perform examinations in the event that
the primary examiner is unavailable. A recorder is pre-
sent for all caries examinations. Primary and back-up
examiners and recorders from all three clinical centers
participated in a four-day calibration session with a gold
standard examiner and were certified by the DCC prior
to the first baseline examinations. They also participate
in refresher and reliability measurement sessions prior
to the 12-, 24-, and 33-month examinations.
Study Outcomes
Primary Outcome Variable
The primary study outcome is the cumulative D2 or
Filled Surface (D2 FS) increment (root and coronal sur-
faces combined) cumulated from baseline through the
three follow-up examinations. Use of the cumulative,
combined D2 FS increment measure allows comparison
with existing literature and increases confidence that
any effect detected represents the prevention cavitation,
which has substantial clinical implications for individuals
who experience it.
The D2 FS increment is computed as the weighted
sum, across tooth surfaces, of changes in surface status
associated with 64 pre-defined transitions in tooth-sur-
face integrity (Table 1). Our weighting scheme assigned
a range of -1, 0, or +1, with transitions to a worse status
receiving positive weights and transitions (reversals) to a
better status receiving negative weights. No reversals are
Table 1 Combined D2FS increment: Scoring weight of changes in tooth surface for primary outcome variable
T1: Second call
T0: First call S [P D1 PD1]D 2 [D3 PD2 PD3] F [FD1]F D 2 [FD3] C [CD1]C D 2 [CD3]YM
S[ PD 1 PD1] 01 1 1 0 0 0 0
D2 [D3 PD2 PD3]- 1 00 0 0 0 0 0
F [FD1]- 1 0 01 00 0 0
FD2 [FD3]- 1 - 1 00 00 0 0
C [CD1]- 1 0 01 01 0 0
CD2 [CD3]- 1 - 1 - 1 00 00 0
Y 00 0 0 0 0 0 0
M 00 0 0 0 0 0 0
S = sound.
P = pit and fissure sealant.
D1 = non-cavitated caries lesion.
D2 = cavitated enamel caries lesion.
D3 = caries lesion penetrating into dentin.
F = filled.
C = crowned.
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that reflects no change (e.g., F to F), a change from D2
to treated status (F or C), or to or from an unscorable
status (Y or M) is scored 0 and hence effectively
excluded from analysis. A transition from sound (S) to
crowned (C) is given a score of 0 to minimize the influ-
ence of non-caries-related treatment on increment
counts. Transition from S to CD2 is considered implau-
sible given annual examinations. After completion of
bootstrapping analyses of a caries increment dataset
from another study, we concluded that the optimal way
to handle unlikely or implausible transitions is to ignore
them (i.e., assign a weight of zero). Hence for our pri-
mary analysis the bolded cells in Table 1 will be ignored,
although they will be included in an outcome in planned
secondary analyses.
Secondary Outcome Variable
The cumulative combined D12FS increment (Table 2) is
a variant of the primary outcome measure that adds
transitions to and from non-cavitated caries (i.e., D1,
PD1,F D 1,C D 1). This measure is constructed by scoring
transitions toward worsening oral health as positive, bio-
logically plausible “reversals” (i.e., remineralization indi-
cated by transition from D1 to S) as negative, and no
change or implausible/impossible as zero, and then sum-
ming over all surfaces examined. Thus, this measure can
take negative values. A maximum weight of 2 is assigned
to transitions observed between a pair of consecutive
examinations that could theoretically be observed as
intermediate steps (each contributing an increment)
over two to three years of follow-up, so that the cumu-
lative increment could not be greater than any single
change. For example, an increment from S to D2 is
given greater weight on the assumption that it should
add the same increment to the cumulative score as two
transitions (S to D1, then D1 to D2).
Other Study Measures
In addition to the caries examination data, other study
data are collected periodically to assist in monitoring
participant safety and as measures of risk factors and
other mediators of caries incidence. Additional data col-
lected at baseline describe participants’ demographic
characteristics, self-reported oral hygiene behaviors,
fluoride exposure, and exposure to antibiotics. Adher-
ence is measured by self- reported lozenge use at each
visit and by the cumulative bottles of lozenges used dur-
ing the study. Staff also query participants as to receipt
of preventive dental care and use of over-the-counter
preventive agents since the last contact. Forms used for
all data collection are available on the study’sp u b l i c
website at http://www.xactstudy.org.
Safety Monitoring
A medical history checklist was collected at baseline,
and is updated at each subsequent examination visit.
Also at every examination visit, participants respond to
questions about side effects and possible serious adverse
events. Participants are also queried regarding side
effects at all between examination telephone calls.





S [P] D1 [PD1]D 2 [D3 PD2 PD3]F F D 1 FD2 [FD3]CC D 1 CD2 [CD3]YM
S [P] 01 2 2 2 2 0 0 0 0 0
D1 [PD1] -1 0 1 1 1 1 1 1 1 0 0
D2 [D3 PD2 PD3]- 2 - 1 00 1 0 0 0 0 0 0
F- 2 - 1 001 2 01 2 0 0
FD1 -2 -2 -1 -1 0 1 1 1 1 0 0
FD2 [FD3]- 2 - 2- 2 0 -1 00 0 00 0
C- 2 - 1 001 2 01 2 0 0
CD1 -2 -2 -1 -1 0 1 -1 0 1 0 0
CD2 [CD3]- 2 - 2- 2 - 2 - 1 00 -1 00 0
Y 00 0 0 0 0 0 0 0 0 0
M 00 0 0 0 0 0 0 0 0 0
S = sound.
P = pit and fissure sealant.
D1 = non-cavitated caries lesion.
D2 = cavitated enamel caries lesion.
D3 = caries lesion penetrating into dentin.
F = filled.
C = crowned.
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All clinical center staff were centrally trained and certi-
fied in all necessary aspects of study operations,
including questionnaire administration and data
entry. Initial training occurred prior to the start of ran-
domization, with recertification occurring about
annually. The data coordinating center monitors study
progress on an ongoing basis and generates regular
trial monitoring reports for review by the study’s Steer-
ing Committee and the Data Safety Monitoring Board
(DSMB). The Data Coordinating Center uses a secure,
web-based application for data entry and management.
This application incorporates real-time error checking
and quality assurance at the time of data entry and
prompts clinical center staff about potentially erro-
neous data during data entry. Additional “back-end”
checks are performed at the data coordinating center.
The data coordinating center maintains an electronic
audit trail of all errors and error resolutions. Finally,
the DCC conducts annual site visits at each clinical
center to check whether data collection, recording, and
entry meet standards for quality assurance as defined
in Good Clinical Practice (GCP) [15].
Sample Size
We based our required sample size on a series of large
longitudinal cohort studiest h a tp e r m i t t e de s t i m a t e so f
expected combined net D2FS increment in the placebo
group of the trial. These studies, reviewed by Griffin
et al. [16] and Thomson [1] did not include measure-
ment of D1 lesions. Although they varied in design,
these studies reported sufficient data to calculate reason-
able values for three-year untreated incidence rates of
root, coronal, and total caries, under the assumption of
constant rates over years. These estimated surface incre-
ments were 1.4, 2.5 and 3.7 respectively. We estimated
the sample size needed, using a range of values (2.3 to
4.9) for the placebo cumulative, combined D2FS incre-
ment over three years, and assuming that the treatment
might result in a 20% reduction, with power set at 80%
and one-sided alpha at 0.025. Using PASS 2005 with a
Poisson regression model and a large, but plausible
overdispersion parameter (3.0, to account for excess
variability), and assuming attrition of 10% per year, we




We expect to have complete data on baseline measures,
so missing data are likely to arise only with respect to
the annual and final examination visits. Since our analy-
sis approach accounts for time at risk, the primary out-
come of combined D2FS increment will be imputed
from baseline to year 1 only for participants who failed
to return for any annual visits, and the time-at-risk will
be defined as the target date for the first annual visit.
We will use an inclusive model to improve the likeli-
hood of unbiased imputed values [17]. We will multiply
impute missing data using data augmentation with Mar-
kov Chain Monte Carlo sampling. Five to eight versions
of the final analysis dataset will be created and analyzed
using identical procedure, followed by combining the
results so that variation between imputation versions is
incorporated in the standard error and p-value.
Primary Outcome Analysis
The primary analyses will be an intent-to-treat (ITT)
analysis, on a sample that includes all randomized
patients and classifies them according to their assigned
treatment group, regardless of their adherence to the
protocol. The primary outcome will be analyzed in a
negative binomial regression model (using SAS® PROC
GENMOD) in which treatment group and clinical cen-
ter indicators are included as fixed categorical design
factors. Planned (ap r i o r i ) covariates are age and age-
squared, intensity of preventive regimen, oral hygiene
behavior measures, and severity of baseline caries, which
is defined as the sum of decayed surfaces at the baseline
examination. We will include the natural log of person-
years at risk, ln(t i), as an offset to adjust for length of
time since the participant was randomized. Formally,
the model is,
ln  T S S ln i1 12 23 i     ii t () =+ + + + ′ + () 0 c   ,
or equivalently,
ln T S S ii 1 1 2 2 3 i     ti () =+ + + + + ′
0 c  ,
where μ is the mean observed increment, μ/t is the
incidence of new progressions per year, T is the treat-
ment indicator (0 = placebo, 1 = xylitol), S1,S 2 are
clinical site indicators, ci represents a vector of covari-
ates, and b and g represent vectors of parameters to
be estimated. The resulting b1 coefficient thus has the
interpretation of the ln(relative risk) for progression
for the xylitol compared to placebo lozenges, and the
null hypothesis test of no difference between treat-
ment arms is a test of H0: b1 =0v s .t h ea l t e r n a t i v e
hypothesis H1: b1 < 0. The actual fraction of a year’s
exposure to the lozenges will be used where known,
otherwise, the offset will be set to the midpoint of the
period between the first examination missed and the
last examination attended. In secondary analyses of
the primary outcome, we will conduct sensitivity ana-
lyses by applying the alternative distributional models
(Poisson, mixture models) mentioned above to the
same data.
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Analyses for three secondary aims are also planned. The
first of these analyses tests the primary hypothesis using
the secondary outcome variable (cumulative combined
D12FS increment). As a part of this analysis we will eval-
uate whether the D12FS increment result provides a
conclusion for the trial in shorter time. Second, we will
compare the intervention’s preventive effects on root
surfaces as distinct from coronal surfaces. Third, we will
examine the impact of lozenge consumption itself on
caries prevention in the control subjects, to check
whether increased salivary flow might account for differ-
ences in the development of new caries, again using the
primary and secondary outcomes.
Discussion
The results of X-ACT should bring some clarity to the
controversy over the effectiveness of xylitol as a caries
preventive agent. Criticism of available evidence has
focused on the design of many of the studies, as well as
the heterogeneity of the results [5-7,18]. The lack of pla-
cebo controls in many of the trials increases the risk of
bias and makes it difficult to disentangle the therapeutic
effects of xylitol from the preventive effects of stimulat-
ing saliva flow and scrubbing tooth surfaces with gum.
In addition, many of the available studies have been
evaluated as being at high risk for bias for a variety of
other problems, including lack of examiner blinding,
lack of examiner calibration, extensive examiner varia-
tion, differences at baseline due possibly to classroom or
school-level randomization, and high attrition [5,18].
X-ACT employs an active placebo control, is rando-
mized, is adequately powered to detect any caries pre-
ventive effect of clinical significance, and adheres to
strict standards for good clinical practice. Thus, the
r e s u l t si tp r o v i d e ss h o u l ds u b s t a n t i a l l ya u g m e n tt h e
existing evidence concerning the effectiveness of xylitol.
Further, and perhaps just as importantly, the results
will extend this knowledge of effectiveness to adults, for
whom so little effectiveness information concerning any
caries preventive intervention is currently available. If
xylitol lozenges prove to be effective in reducing caries
increments in caries-active adults, the intervention
would offer such individuals who either do not utilize
dental services regularly, or who do not receive caries
preventive treatment in the dental office a relatively
low-cost, user-controlled caries preventive method.
The inclusion of non-cavitated lesions in the second-
ary analysis raises some interesting issues with regard to
t h er e l a t i v ew e i g h tg i v e nt h e s el e s i o n si nt h ea n a l y s i s
compared to cavitated lesions. We have stated ap r i o r i
our weighting scheme, but plan to analyze variations on
this matrix to determine the sensitivity of the increment
scores to several of our weighting decisions. Also,
because both cavitated and non-cavitated lesions are
recorded in this trial, the results should offer insight
into the possibility of shortening caries trials by basing
the principal analysis on non-cavitated lesion incre-
ments. Should a shorter trial be shown to be feasible in
retrospect, this will have important implications for
future caries trials. The typical three year duration and
associated costs of such trials, has contributed to the
reduction in such controlled studies in recent decades.
Yet the need for this type of unbiased research result
for caries preventive agents is undiminished, as dis-
cussed above.
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